Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | CACNA1G | O43497 | 3/20 | 0.34 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2869042 | 0.94 | KCNH2 (0.46) | NPSR1KCNH2CACNA1GCHRM3 | |
| SCHEMBL2868801 | 0.91 | NPSR1 (0.39) | NPSR1CACNA1G | |
| SCHEMBL2871903 | 0.89 | NPSR1 (0.40) | NPSR1CACNA1GCHRM3 | |
| SCHEMBL2856589 | 0.88 | NPSR1 (0.39) | NPSR1DRD2CHRM3 | |
| SCHEMBL2863242 | 0.87 | HRH3 (0.44) | NPSR1DRD2 | |
| SCHEMBL2861560 | 0.86 | CCR1 (0.42) | NPSR1 | |
| SCHEMBL2866704 | 0.85 | NPSR1 (0.38) | NPSR1KCNH2 | |
| SCHEMBL5582084 | 0.84 | NPSR1 (0.37) | NPSR1 | |
| SCHEMBL2870601 | 0.84 | NPSR1 (0.39) | NPSR1 | |
| SCHEMBL2870931 | 0.84 | HTT (0.42) | NPSR1CACNA1G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795267-B2 | Bicyclic piperazine compound having TGR23 antagonistic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-14 | — | — | US | disclosed |
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | GPR3, FFAR3, LPAR3 | NPSR1 211/4885KCNH2 856/4885DRD2 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.